Matrix-induced autologous chondrocyte implantation of talus articular defects

Eric Giza, Martin Sullivan, Dan Ocel, Gregory Lundeen, Matthew E. Mitchell, Lindsey Veris, Judie Walton

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: Osteochondral injury of the talus can be challenging to treat because the damaged articular cartilage has a poor intrinsic reparative capability. Autologous Chondrocyte Implantation has become an effective means for treating persistent cartilage lesions that fail to respond to routine ankle arthroscopy. The purpose of this study was to assess the results of Matrix-induced autologous chondrocyte implantation (MACI) for the treatment of osteochondral defects of the talar dome using a technique which does not require an osteotomy of the tibia or fibula. Materials and Methods: A prospective investigation of MACI was performed on ten patients with full-thickness lesions of the talus. The patients had a documented talus lesion on MRI, failure of conservative treatment and arthroscopic debridement/curettage, persistent ankle pain and swelling, the absence of tibiotalar arthritis and a stable ankle. Five males and five females, with an average of 1.7 previous procedures prior to Matrix-induced autologous implantation, were included in this study. All patients were available for followup at 1 and 2 years. Lesions were graded during the harvesting procedure using the Cheng-Ferkel grading system, the Outerbridge classification, and the International Cartilage Repair Society system. Clinical and functional evaluation was done preoperatively, and at 1 and 2 years postoperatively using the AOFAS hindfoot evaluation and the SF-36 Health Survey. Results: Preoperative AOFAS hindfoot scores were 61.2 (range, 42 to 76) which improved 1 year postoperatively to 74.7 (range, 46 to 87) (p < 0.05) and 2 years postoperatively to 73.3 (range, 42 to 90) (p = 0.151). At both 1 and 2 years postoperatively, the results of the SF36 evaluation demonstrated a significant improvement in the Physical Functioning (p = 0.002) and Bodily Pain (p < 0.001) components. Subjectively, all ten patients believed this procedure helped them. Conclusion: The results of this study suggest that MACI may be an effective way to treat full-thickness lesions of the talus using harvested chondrocytes from the talus without malleolar osteotomy. We recommend it for patients who do not respond to initial curettage and microfracture.

Original languageEnglish (US)
Pages (from-to)747-753
Number of pages7
JournalFoot and Ankle International
Volume31
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Talus
Chondrocytes
Joints
Ankle
Curettage
Osteotomy
Cartilage
Pain
Stress Fractures
Fibula
Arthroscopy
Articular Cartilage
Debridement
Health Surveys
Tibia
Arthritis
Wounds and Injuries

Keywords

  • Autologous chondrocyte implantation
  • Malleolus osteotomy
  • Microfracture
  • Osteochondral defect
  • Talus

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Giza, E., Sullivan, M., Ocel, D., Lundeen, G., Mitchell, M. E., Veris, L., & Walton, J. (2010). Matrix-induced autologous chondrocyte implantation of talus articular defects. Foot and Ankle International, 31(9), 747-753. https://doi.org/10.3113/FAI.2010.0747

Matrix-induced autologous chondrocyte implantation of talus articular defects. / Giza, Eric; Sullivan, Martin; Ocel, Dan; Lundeen, Gregory; Mitchell, Matthew E.; Veris, Lindsey; Walton, Judie.

In: Foot and Ankle International, Vol. 31, No. 9, 09.2010, p. 747-753.

Research output: Contribution to journalArticle

Giza, E, Sullivan, M, Ocel, D, Lundeen, G, Mitchell, ME, Veris, L & Walton, J 2010, 'Matrix-induced autologous chondrocyte implantation of talus articular defects', Foot and Ankle International, vol. 31, no. 9, pp. 747-753. https://doi.org/10.3113/FAI.2010.0747
Giza, Eric ; Sullivan, Martin ; Ocel, Dan ; Lundeen, Gregory ; Mitchell, Matthew E. ; Veris, Lindsey ; Walton, Judie. / Matrix-induced autologous chondrocyte implantation of talus articular defects. In: Foot and Ankle International. 2010 ; Vol. 31, No. 9. pp. 747-753.
@article{157ff2a7c5004a1dae37ae50877b254e,
title = "Matrix-induced autologous chondrocyte implantation of talus articular defects",
abstract = "Background: Osteochondral injury of the talus can be challenging to treat because the damaged articular cartilage has a poor intrinsic reparative capability. Autologous Chondrocyte Implantation has become an effective means for treating persistent cartilage lesions that fail to respond to routine ankle arthroscopy. The purpose of this study was to assess the results of Matrix-induced autologous chondrocyte implantation (MACI) for the treatment of osteochondral defects of the talar dome using a technique which does not require an osteotomy of the tibia or fibula. Materials and Methods: A prospective investigation of MACI was performed on ten patients with full-thickness lesions of the talus. The patients had a documented talus lesion on MRI, failure of conservative treatment and arthroscopic debridement/curettage, persistent ankle pain and swelling, the absence of tibiotalar arthritis and a stable ankle. Five males and five females, with an average of 1.7 previous procedures prior to Matrix-induced autologous implantation, were included in this study. All patients were available for followup at 1 and 2 years. Lesions were graded during the harvesting procedure using the Cheng-Ferkel grading system, the Outerbridge classification, and the International Cartilage Repair Society system. Clinical and functional evaluation was done preoperatively, and at 1 and 2 years postoperatively using the AOFAS hindfoot evaluation and the SF-36 Health Survey. Results: Preoperative AOFAS hindfoot scores were 61.2 (range, 42 to 76) which improved 1 year postoperatively to 74.7 (range, 46 to 87) (p < 0.05) and 2 years postoperatively to 73.3 (range, 42 to 90) (p = 0.151). At both 1 and 2 years postoperatively, the results of the SF36 evaluation demonstrated a significant improvement in the Physical Functioning (p = 0.002) and Bodily Pain (p < 0.001) components. Subjectively, all ten patients believed this procedure helped them. Conclusion: The results of this study suggest that MACI may be an effective way to treat full-thickness lesions of the talus using harvested chondrocytes from the talus without malleolar osteotomy. We recommend it for patients who do not respond to initial curettage and microfracture.",
keywords = "Autologous chondrocyte implantation, Malleolus osteotomy, Microfracture, Osteochondral defect, Talus",
author = "Eric Giza and Martin Sullivan and Dan Ocel and Gregory Lundeen and Mitchell, {Matthew E.} and Lindsey Veris and Judie Walton",
year = "2010",
month = "9",
doi = "10.3113/FAI.2010.0747",
language = "English (US)",
volume = "31",
pages = "747--753",
journal = "Foot and Ankle International",
issn = "1071-1007",
publisher = "AOFAS - American Orthopaedic Foot and Ankle Society",
number = "9",

}

TY - JOUR

T1 - Matrix-induced autologous chondrocyte implantation of talus articular defects

AU - Giza, Eric

AU - Sullivan, Martin

AU - Ocel, Dan

AU - Lundeen, Gregory

AU - Mitchell, Matthew E.

AU - Veris, Lindsey

AU - Walton, Judie

PY - 2010/9

Y1 - 2010/9

N2 - Background: Osteochondral injury of the talus can be challenging to treat because the damaged articular cartilage has a poor intrinsic reparative capability. Autologous Chondrocyte Implantation has become an effective means for treating persistent cartilage lesions that fail to respond to routine ankle arthroscopy. The purpose of this study was to assess the results of Matrix-induced autologous chondrocyte implantation (MACI) for the treatment of osteochondral defects of the talar dome using a technique which does not require an osteotomy of the tibia or fibula. Materials and Methods: A prospective investigation of MACI was performed on ten patients with full-thickness lesions of the talus. The patients had a documented talus lesion on MRI, failure of conservative treatment and arthroscopic debridement/curettage, persistent ankle pain and swelling, the absence of tibiotalar arthritis and a stable ankle. Five males and five females, with an average of 1.7 previous procedures prior to Matrix-induced autologous implantation, were included in this study. All patients were available for followup at 1 and 2 years. Lesions were graded during the harvesting procedure using the Cheng-Ferkel grading system, the Outerbridge classification, and the International Cartilage Repair Society system. Clinical and functional evaluation was done preoperatively, and at 1 and 2 years postoperatively using the AOFAS hindfoot evaluation and the SF-36 Health Survey. Results: Preoperative AOFAS hindfoot scores were 61.2 (range, 42 to 76) which improved 1 year postoperatively to 74.7 (range, 46 to 87) (p < 0.05) and 2 years postoperatively to 73.3 (range, 42 to 90) (p = 0.151). At both 1 and 2 years postoperatively, the results of the SF36 evaluation demonstrated a significant improvement in the Physical Functioning (p = 0.002) and Bodily Pain (p < 0.001) components. Subjectively, all ten patients believed this procedure helped them. Conclusion: The results of this study suggest that MACI may be an effective way to treat full-thickness lesions of the talus using harvested chondrocytes from the talus without malleolar osteotomy. We recommend it for patients who do not respond to initial curettage and microfracture.

AB - Background: Osteochondral injury of the talus can be challenging to treat because the damaged articular cartilage has a poor intrinsic reparative capability. Autologous Chondrocyte Implantation has become an effective means for treating persistent cartilage lesions that fail to respond to routine ankle arthroscopy. The purpose of this study was to assess the results of Matrix-induced autologous chondrocyte implantation (MACI) for the treatment of osteochondral defects of the talar dome using a technique which does not require an osteotomy of the tibia or fibula. Materials and Methods: A prospective investigation of MACI was performed on ten patients with full-thickness lesions of the talus. The patients had a documented talus lesion on MRI, failure of conservative treatment and arthroscopic debridement/curettage, persistent ankle pain and swelling, the absence of tibiotalar arthritis and a stable ankle. Five males and five females, with an average of 1.7 previous procedures prior to Matrix-induced autologous implantation, were included in this study. All patients were available for followup at 1 and 2 years. Lesions were graded during the harvesting procedure using the Cheng-Ferkel grading system, the Outerbridge classification, and the International Cartilage Repair Society system. Clinical and functional evaluation was done preoperatively, and at 1 and 2 years postoperatively using the AOFAS hindfoot evaluation and the SF-36 Health Survey. Results: Preoperative AOFAS hindfoot scores were 61.2 (range, 42 to 76) which improved 1 year postoperatively to 74.7 (range, 46 to 87) (p < 0.05) and 2 years postoperatively to 73.3 (range, 42 to 90) (p = 0.151). At both 1 and 2 years postoperatively, the results of the SF36 evaluation demonstrated a significant improvement in the Physical Functioning (p = 0.002) and Bodily Pain (p < 0.001) components. Subjectively, all ten patients believed this procedure helped them. Conclusion: The results of this study suggest that MACI may be an effective way to treat full-thickness lesions of the talus using harvested chondrocytes from the talus without malleolar osteotomy. We recommend it for patients who do not respond to initial curettage and microfracture.

KW - Autologous chondrocyte implantation

KW - Malleolus osteotomy

KW - Microfracture

KW - Osteochondral defect

KW - Talus

UR - http://www.scopus.com/inward/record.url?scp=77956638142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956638142&partnerID=8YFLogxK

U2 - 10.3113/FAI.2010.0747

DO - 10.3113/FAI.2010.0747

M3 - Article

C2 - 20880476

AN - SCOPUS:77956638142

VL - 31

SP - 747

EP - 753

JO - Foot and Ankle International

JF - Foot and Ankle International

SN - 1071-1007

IS - 9

ER -